Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 469 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: breast biopsy Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

NCT01219075
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography
Dietary Supplement · Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Not applicable Interventional

Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings

NCT03929783
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Contrast Enhanced Digital Mammography
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Not applicable Interventional

Infrared Imaging for Breast Cancer Modeling

NCT03990012
View directory record Official record
Conditions
Breast Cancer
Interventions
IR Imaging, 3D Scanning
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 17, 2026, 11:51 PM EDT
Active, not recruiting No phase listed Observational

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

NCT03281902
View directory record Official record
Conditions
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 11:51 PM EDT
Withdrawn Phase 2 Interventional

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

NCT05539365
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Alpha-type-1 Polarized Dendritic Cells, Biopsy, Computed Tomography, Leukapheresis, Pembrolizumab, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 17, 2026, 11:51 PM EDT
Completed No phase listed Observational

Case Collection Study in the Evaluation of Doubling Time Rates in Non-Suspicious Breast Masses Using QT Ultrasound Technology

NCT03470051
View directory record Official record
Conditions
Breast Fibroadenoma
Interventions
QT Ultrasound
Diagnostic Test
Lead sponsor
QT Ultrasound LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Long Beach, California • Novato, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 17, 2026, 11:51 PM EDT
Terminated No phase listed Observational

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

NCT05414123
View directory record Official record
Conditions
Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer, Non-Small Cell Lung Cancer
Interventions
CNSide
Device
Lead sponsor
Biocept, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 17, 2026, 11:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018
View directory record Official record
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
Interventions
Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Foxborough, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 17, 2026, 11:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cone Beam CT for Breast Imaging

NCT01880580
View directory record Official record
Conditions
Breast Imaging, Breast Cancer
Interventions
Not listed
Lead sponsor
Koning Corporation
Industry
Eligibility
40 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 17, 2026, 11:51 PM EDT
Active, not recruiting Not applicable Interventional

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer

NCT03255577
View directory record Official record
Conditions
Breast Cancer, Locally Advanced Breast Cancer
Interventions
Sentinel Lymph Node Biopsy (SLNB)
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 17, 2026, 11:51 PM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy

NCT02610621
View directory record Official record
Conditions
Breast Cancer
Interventions
Lumpectomy without sentinel node biopsy
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 17, 2026, 11:51 PM EDT
Active, not recruiting Phase 1 Interventional

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT02453620
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 11:51 PM EDT
Terminated Phase 2 Interventional Results available

Aging Mammary Stem Cells and Breast Cancer Prevention

NCT02642094
View directory record Official record
Conditions
Cancer of Breast
Interventions
Rapamycin
Drug
Lead sponsor
LuZhe Sun
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies

NCT00721903
View directory record Official record
Conditions
Breast Cancers
Interventions
Ultrasound Scan, Mammography and Ultrasound
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

NCT02321527
View directory record Official record
Conditions
Breast Cancer
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement, Phone Call
Drug · Device · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Early Phase 1 Interventional

S-equol in Women With Triple Negative Breast Cancer

NCT02352025
View directory record Official record
Conditions
Breast Cancer
Interventions
S-equol
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy

NCT00734838
View directory record Official record
Conditions
Breast Cancer
Interventions
High Resolution Microendoscope
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 17, 2026, 11:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

NCT03400215
View directory record Official record
Conditions
Breast Cancer
Interventions
Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Not applicable Interventional

Second Echelon Node Study With Methylene Blue

NCT01823172
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Methylene blue dye injection of sentinel lymph node
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available

SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer

NCT03294330
View directory record Official record
Conditions
Sentinel Lymph Node, Melanoma (Skin), Breast Cancer
Interventions
IC-Green KIT
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Poughkeepsie, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 17, 2026, 11:51 PM EDT
Recruiting Phase 2 Interventional

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

NCT07069595
View directory record Official record
Conditions
Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
Interventions
Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing
Drug · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 17, 2026, 11:51 PM EDT
Recruiting Not applicable Interventional

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

NCT06085833
View directory record Official record
Conditions
Breast Cancer
Interventions
Nanomechanical Phenotype Test
Diagnostic Test
Lead sponsor
ARTIDIS AG
Industry
Eligibility
18 Years and older
Enrollment
2,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 11:51 PM EDT
Completed Phase 2 Interventional Results available

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

NCT03179904
View directory record Official record
Conditions
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
Interventions
Anastrozole, Denifanstat, Exemestane, Fulvestrant, Echocardiography, Letrozole, Paclitaxel, Trastuzumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 11:51 PM EDT